2.53
price up icon0.80%   0.02
after-market Handel nachbörslich: 2.53
loading
Schlusskurs vom Vortag:
$2.51
Offen:
$2.5098
24-Stunden-Volumen:
15,240
Relative Volume:
0.85
Marktkapitalisierung:
$72.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.32%
1M Leistung:
-7.33%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$2.33
$2.59
1-Wochen-Bereich:
Value
$2.33
$2.66
52-Wochen-Spanne:
Value
$2.33
$3.09

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name
Firmenname
Insight Molecular Diagnostics Inc
Name
Telefon
949-409-7600
Name
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Name
Mitarbeiter
49
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
IMDX's Discussions on Twitter

Vergleichen Sie IMDX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
IMDX
Insight Molecular Diagnostics Inc
2.53 71.84M 0 0 0 0.00
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
492.72 184.93B 43.21B 6.58B 6.17B 17.29
Diagnostics & Research icon
DHR
Danaher Corp
205.82 147.00B 24.01B 3.41B 4.86B 4.70
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
647.09 51.77B 4.04B 985.66M 774.34M 12.01
Diagnostics & Research icon
A
Agilent Technologies Inc
125.66 35.50B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
190.81 32.08B 15.70B 1.24B 2.01B 6.91

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-28 Eingeleitet Lake Street Buy
2022-05-24 Herabstufung Stephens Overweight → Equal-Weight
2022-03-14 Herabstufung KeyBanc Capital Markets Overweight → Sector Weight
2022-01-07 Eingeleitet Stephens Overweight
2022-01-06 Fortgesetzt Piper Sandler Overweight
2021-03-17 Fortgesetzt Needham Buy
2021-01-07 Hochstufung The Benchmark Company Speculative Buy → Buy
2020-12-16 Hochstufung Piper Sandler Neutral → Overweight
2020-11-30 Eingeleitet BTIG Research Buy
2020-11-10 Eingeleitet KeyBanc Capital Markets Overweight
2020-07-30 Bestätigt The Benchmark Company Speculative Buy
2020-07-01 Herabstufung Piper Sandler Overweight → Neutral
2020-06-30 Herabstufung Chardan Capital Markets Buy → Neutral
2020-06-02 Eingeleitet Needham Buy
2019-02-13 Eingeleitet Piper Jaffray Overweight
2019-01-29 Hochstufung Janney Neutral → Buy
2018-12-19 Fortgesetzt Lake Street Buy
Alle ansehen

Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten

pulisher
Aug 26, 2025

iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire

Aug 26, 2025
pulisher
Aug 26, 2025

iMDx Announces Participation in NYC Investment Conferences - AInvest

Aug 26, 2025
pulisher
Aug 26, 2025

Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan

Aug 26, 2025
pulisher
Aug 25, 2025

iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest

Aug 25, 2025
pulisher
Aug 25, 2025

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener

Aug 25, 2025
pulisher
Aug 23, 2025

HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.

Aug 23, 2025
pulisher
Aug 19, 2025

Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com

Aug 19, 2025
pulisher
Aug 19, 2025

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 19, 2025
pulisher
Aug 18, 2025

Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com

Aug 18, 2025
pulisher
Aug 18, 2025

Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest

Aug 18, 2025
pulisher
Aug 15, 2025

Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Aug 14, 2025
pulisher
Aug 13, 2025

Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 13, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 12, 2025

Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post

Aug 12, 2025
pulisher
Aug 12, 2025

Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks

Aug 12, 2025
pulisher
Aug 11, 2025

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log

Aug 11, 2025
pulisher
Aug 11, 2025

Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada

Aug 11, 2025
pulisher
Aug 11, 2025

Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus

Aug 11, 2025
pulisher
Aug 10, 2025

IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛

Aug 10, 2025
pulisher
Aug 08, 2025

Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 08, 2025

Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent

Aug 08, 2025
pulisher
Aug 07, 2025

Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us

Aug 07, 2025
pulisher
Aug 06, 2025

PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com

Aug 06, 2025
pulisher
Aug 06, 2025

Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest

Aug 06, 2025
pulisher
Aug 04, 2025

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times

Aug 04, 2025
pulisher
Aug 04, 2025

iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire

Aug 04, 2025
pulisher
Aug 04, 2025

iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan

Aug 04, 2025
pulisher
Aug 01, 2025

Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech

Aug 01, 2025
pulisher
Jul 30, 2025

IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire

Jul 30, 2025
pulisher
Jul 30, 2025

Revolutionary Transplant Test Achieves 79% Accuracy, Nearly Doubles Industry Standard in Detecting Organ Rejection - Stock Titan

Jul 30, 2025
pulisher
Jul 30, 2025

U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com

Jul 30, 2025
pulisher
Jul 28, 2025

iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire

Jul 28, 2025
pulisher
Jul 28, 2025

Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan

Jul 28, 2025
pulisher
Jul 25, 2025

Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail

Jul 25, 2025
pulisher
Jul 24, 2025

Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest

Jul 24, 2025
pulisher
Jul 21, 2025

Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest

Jul 21, 2025

Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)

Es liegen keine Finanzdaten für Insight Molecular Diagnostics Inc (IMDX) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
diagnostics_research WAT
$301.80
price up icon 1.39%
diagnostics_research DGX
$181.64
price up icon 1.36%
$168.25
price up icon 0.22%
diagnostics_research LH
$277.99
price up icon 0.98%
diagnostics_research MTD
$1,301.04
price up icon 1.40%
diagnostics_research IQV
$190.81
price up icon 1.10%
Kapitalisierung:     |  Volumen (24h):